Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II Receptor Blocker Monotherapy

被引:3
作者
Neutel, Joel [1 ]
Shojaee, Ali [2 ]
Maa, Jen-Fue [2 ]
机构
[1] Orange Cty Res Ctr, Dept Clin Pharmacol, Tustin, CA 92780 USA
[2] Daiichi Sankyo Inc, Parsippany, NJ USA
关键词
Amlodipine; Angiotensin II receptor blocker; Blood pressure; Calcium channel blocker; Combination therapy; Hydrochlorothiazide; Hypertension; Olmesartan medoxomil; OLMESARTAN MEDOXOMIL; BLOOD-PRESSURE; COMBINATION; AMLODIPINE; TRIAL;
D O I
10.1007/s12325-012-0030-z
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
While monotherapy is often recommended as initial treatment, most patients require dose escalation and add-on agents to achieve their blood pressure (BP) goal. This secondary analysis evaluated the efficacy and safety of initiating patients on a regimen of fixed-dose amlodipine (AML)/olmesartan medoxomil (OM) +/- hydrochlorothiazide (HCTZ) who were uncontrolled on prior monotherapy with a calcium channel blocker (CCB) or angiotensin II receptor blocker (ARB). Patients uncontrolled on prior monotherapy with CCB or ARB therapy were initiated on AML/OM 5/20 mg and up-titrated every 4 weeks to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 + HCTZ 12.5 mg, and AML/OM 10/40 + HCTZ 25 mg. Patients were up-titrated to a higher AML/OM dose if mean seated cuff BP (SeBP) was a parts per thousand yen120/70 mmHg, and up-titrated to any HCTZ dose if mean SeBP was a parts per thousand yen125/75 mmHg. The primary efficacy endpoint was the cumulative proportion of patients achieving a seated cuff systolic BP (SeSBP) goal of < 140 mmHg (< 130 mmHg for patients with diabetes) after 12 weeks. Secondary endpoints included mean change from baseline in SeBP and ambulatory BP, ambulatory BP target achievement, and safety. For the prior CCB (n = 118; baseline SeBP: 153.4/91.5 mmHg) and ARB (n = 237; 154.6/92.6 mmHg) groups, SeSBP goal achievement after 12 weeks was 72.7% and 76.9%, respectively. Mean changes (+/- SE) from baseline in SeBP were dose proportional for prior CCB and ARB patients, ranging from -9.9 (+/- 1.25)/-5.8 (+/- 0.83) mmHg and -13.9 (+/- 0.79)/-7.6 (+/- 0.47) mmHg at the AML/OM 5/20 mg dose, respectively, to -21.8 (+/- 1.68)/-11.6 (+/-.12) mmHg and -26.2 (+/- 1.31)/-15.0 (+/- 0.86) mmHg at the AML/OM 10/40 mg + HCTZ 25 mg dose (P < 0.0001 for all). An AML/OM-based titration regimen was efficacious in achieving BP goal in patients uncontrolled on prior monotherapy with a CCB or ARB.
引用
收藏
页码:508 / 523
页数:16
相关论文
共 50 条
[31]   Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients [J].
Matsui, Yoshio ;
Eguchi, Kazuo ;
O'Rourke, Michael F. ;
Ishikawa, Joji ;
Miyashita, Hiroshi ;
Shimada, Kazuyuki ;
Kario, Kazuomi .
HYPERTENSION, 2009, 54 (04) :716-U62
[32]   Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability [J].
Saruta, Takao ;
Ogihara, Toshio ;
Saito, Ikuo ;
Rakugi, Hiromi ;
Shimamoto, Kazuaki ;
Matsuoka, Hiroaki ;
Teramukai, Satoshi ;
Higaki, Jitsuo ;
Ito, Sadayoshi ;
Shimada, Kazuyuki .
HYPERTENSION RESEARCH, 2015, 38 (02) :132-136
[33]   Efficacy and Safety of Angiotensin II Type 1 Receptor Blocker/Calcium Channel locker Combination Therapy for Hypertension: Focus on a Single-pill Fixed-dose Combination of Valsartan and Amlodipine [J].
Miura, S. ;
Saku, K. .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2012, 40 (01) :1-9
[34]   Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease [J].
Nutahara, K ;
Higashihara, E ;
Horie, S ;
Kamura, K ;
Tsuchiya, K ;
Mochizuki, T ;
Hosoya, T ;
Nakayama, T ;
Yamamoto, N ;
Higaki, Y ;
Shimizu, T .
NEPHRON CLINICAL PRACTICE, 2005, 99 (01) :C18-C23
[35]   Hydrochlorothiazide Versus Calcium Channel Blockers: What is the Best Add-on to a Renin-Angiotensin System Blocker for Treating Hypertension in Patients with Renal Disease? [J].
Lerma, Edgar V. .
CURRENT HYPERTENSION REPORTS, 2011, 13 (05) :386-395
[36]   The Role of Angiotensin Receptor Blocker and Calcium Channel Blocker Combination Therapy in Treating Hypertension Focus on Recent Studies [J].
Chrysant, Steven G. .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2010, 10 (05) :315-320
[37]   Protective Effects of an Angiotensin II Receptor Blocker and a Long-Acting Calcium Channel Blocker against Cardiovascular Organ Injuries in Hypertensive Patients [J].
Toshihiko Ishimitsu ;
Tsutomu Kobayashi ;
Takeaki Honda ;
Masaki Takahashi ;
Junichi Minami ;
Satoshi Ohta ;
Hideki Inada ;
Masayoshi Yoshii ;
Hidehiko Ono ;
Hiroaki Matsuoka .
Hypertension Research, 2005, 28 :351-359
[38]   Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension [J].
Johji Kato ;
Naoto Yokota ;
Noboru Tamaki ;
Sumito Kariya ;
Toshihiro Kita ;
Takao Ayabe ;
Tanenao Eto ;
Kazuo Kitamura .
Hypertension Research, 2011, 34 :331-335
[39]   Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients [J].
Ishimitsu, T ;
Kobayashi, T ;
Honda, T ;
Takahashi, M ;
Minami, J ;
Ohta, S ;
Inada, H ;
Yoshii, M ;
Ono, H ;
Matsuoka, H .
HYPERTENSION RESEARCH, 2005, 28 (04) :351-359
[40]   An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone [J].
Kim-Mitsuyama, Shokei ;
Ogawa, Hisao ;
Matsui, Kunihiko ;
Jinnouchi, Tomio ;
Jinnouchi, Hideaki ;
Arakawa, Kikuo .
KIDNEY INTERNATIONAL, 2013, 83 (01) :167-176